Pediatric multiple sclerosis

Opinion statement The diagnosis of multiple sclerosis (MS) in a child remains challenging, given the limited diagnostic criteria and the somewhat poorly defined overlap with acute disseminated encephalomyelitis. Although there are many similarities between pediatric-onset and adult-onset MS, an earl...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Current treatment options in neurology Ročník 11; číslo 3; s. 203 - 210
Hlavní autoři: Waubant, Emmanuelle, Chabas, Dorothee
Médium: Journal Article
Jazyk:angličtina
Vydáno: New York Current Science Inc 01.05.2009
Témata:
Critical Care Medicine
Diabetes
Family Medicine
General Practice
Intensive
Internal Medicine
Medicine
Medicine & Public Health
Neurology
Ophthalmology
Multiple Sclerosis
Glatiramer Acetate
Clinically Isolate Syndrome
Neuromyelitis Optica
Acute Disseminate Encephalomyelitis
ISSN:1092-8480, 1534-3138
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Opinion statement The diagnosis of multiple sclerosis (MS) in a child remains challenging, given the limited diagnostic criteria and the somewhat poorly defined overlap with acute disseminated encephalomyelitis. Although there are many similarities between pediatric-onset and adult-onset MS, an earlier age at disease presentation seems to be associated with specific features such as more frequent encephalopathy, seizures, and brainstem and cerebellar symptoms during the first event. In addition, the initial brain MRI scan of younger patients shows more frequent involvement of the posterior fossa and higher numbers of ovoid, ill-defined T2-bright foci that often partially resolve on the follow-up scan, thereby challenging early diagnosis. Finally, the spinal fluid in younger patients may fail to reveal oligoclonal bands or elevated IgG index at disease onset. No therapy for MS in children has been approved by the US Food and Drug Administration. As a result, physicians have started to use off-label drugs approved for adults. Recent data suggest that some children experience a disease breakthrough on first-line therapies approved for adult MS, and thus second-line therapies must be considered.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1092-8480
1534-3138
DOI:10.1007/s11940-009-0024-6